**Interactions with Lenacapavir**

None

**Residual LEN may affect exposure of sensitive CYP3A4 substrates**

QT interactions shown are with RPV.

Pharmacokinetic interactions shown are mostly with RPV.

**Ezetimibe**

**Evolocumab**

**Alirocumab**

**Other**

- **Gemfibrozil**

**Fibrates**

- **Bezafibrate**

- **Clodibrate**

- **Fenofibrate**

**Interactions with CAB/RPV long acting injections**

Pharmacokinetic interactions shown are mostly with RPV. QT interactions shown are with RPV.

**Interactions with Lenacapavir**

Residual LEN may affect exposure of sensitive CYP3A4 substrates initiated within 9 months after stopping subcutaneous LEN.

**Interactions with Ibalizumab**

None

### Colour Legend

- No clinically significant interaction expected.
- These drugs should not be coadministered.
- Potential interaction which may require a dose adjustment or close monitoring.
- Potential interaction predicted to be of weak intensity.
- No a priori dosage adjustment is recommended.

### Text Legend

- ↑ Potential increased exposure of the lipid-lowering drug
- ↓ Potential decreased exposure of the lipid-lowering drug
- ↔ No significant effect

**Numbers**

Numbers refer to increase or decrease in AUC as observed in drug-drug interaction studies.

**Notes**

a Coadministration with unboosted atazanavir increased pitavastatin AUC by 31%.